Shkhyan R, et al. (2023) Inhibition of a signaling modality within the gp130 receptor enhances tissue regeneration and mitigates osteoarthritis. Sci Transl Med 15, eabq2395 36947594

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

Y757-p - gp130 (mouse) ▲

Modsite: STASTVQySTVVHSG SwissProt Entrez-Gene Orthologous residues gp130 (human): Y759‑p, gp130 iso2 (human): ‑, gp130 iso3 (human): Y698‑p, gp130 (mouse): Y757‑p, gp130 (rat): Y758‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  chondrocyte Cellular systems studied:  primary cells Species studied:  pig Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes R805 decrease Downstream Regulation Effect of modification (process):  signaling pathway regulation, transcription, altered Comments:  regulates Src and MAPK/ERK signaling

Y812-p - gp130 (mouse) ▲

Modsite: EILPRQPyFKQNCsQ SwissProt Entrez-Gene Orthologous residues gp130 (human): Y814‑p, gp130 iso2 (human): ‑, gp130 iso3 (human): Y753‑p, gp130 (mouse): Y812‑p, gp130 (rat): Y813‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  chondrocyte, fibroblast, splenocyte Cellular systems studied:  primary cells, tissue Species studied:  mouse, pig Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes development increase oncostatin_M no change compared to control IL-6 no change compared to control IL-11 no change compared to control LIF no change compared to control oncostatin_M increase in pig chondrocyte R805 oncostatin_M inhibit treatment-induced increase Downstream Regulation Effect of modification (process):  signaling pathway regulation, transcription, altered Comments:  regulates Src and MAPK/ERK signaling

Y904-p - gp130 (mouse) ▲

Modsite: DEEIPKSyLPQTVRQ SwissProt Entrez-Gene Orthologous residues gp130 (human): Y905‑p, gp130 iso2 (human): ‑, gp130 iso3 (human): Y844‑p, gp130 (mouse): Y904‑p, gp130 (rat): Y905‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  chondrocyte Cellular systems studied:  primary cells Species studied:  pig Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes R805 no change compared to control Downstream Regulation Effect of modification (process):  signaling pathway regulation, transcription, altered Comments:  regulates Src and MAPK/ERK signaling